“…For example, the models of ischemic injury, spinal ischemia (Kiymaz et al, 2008), focal cerebral ischemia (Zhang et al, 2006), and middle cerebral artery occlusion (MCAO; Menniti et al, 2009) all differed. The phosphodiesterase antagonist investigated also differed: sildenafil (Kiymaz et al, 2008;Zhang et al, 2006) or PF-5 (Menniti et al, 2009). The duration and route of drug administration varied: 1 day, IP (Kiymaz et al, 2008), 6 days, oral (Zhang et al, 2006), or 7 days, subcutaneous (Menniti et al, 2009).…”